The Veterinary Record Link to Vetlife website
HOME CURRENT ISSUE TABLE OF CONTENTS ARCHIVE SEARCH SUBSCRIPTIONS JOBS FEEDBACK HELP
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobs, A. A. C.
Right arrow Articles by Loeffen, P. L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, A. A. C.
Right arrow Articles by Loeffen, P. L. W.

The Veterinary Record, Vol 139, Issue 10, 225-228
Copyright © 1996 by British Veterinary Association

Protection of experimentally infected pigs by suilysin, the thiol-activated haemolysin of Streptococcus suis

A. A. C. Jacobs BSc, PhD1, A. J. G. van den Berg 1, and P. L. W. Loeffen 1

1 Bacteriological Research Department, Intervet International BV, PO Box 31, 5830 AA Boxmeer, The Netherlands

Three groups of three pigs were vaccinated either with vaccine VAC-SLY, containing purified suilysin derived from Streptococcus suis strain P1/7 (serotype 2), or with vaccine VAC-SCF, containing most of the other extracellular antigens produced by strain P1/7 (but essentially free from suilysin), or with a placebo vaccine. The pigs were vaccinated twice at four weeks and six weeks of age and were challenged intravenously with S suis strain P1/7 at eight weeks of age. On the day of challenge, only the VAC-SLY vaccinated pigs showed an increase in haemolysin neutralisation titre. After challenge the placebo vaccinated pigs developed severe clinical signs characterised by lameness involving several joints, a depressed appearance, high temperatures and/or neurological signs. The VAC-SCF vaccinated pigs showed the same clinical signs but less severely. The VAC-SLY vaccinated pigs were the least affected and showed only mild signs which subsided more quickly than those of the other groups. A post mortem investigation and histology of brain tissue samples confirmed the clinical findings; fibrinous arthritis was less severe and less frequently observed in the VAC-SLY vaccinated pigs than in the VAC-SCF or placebo vaccinated pigs, and none of the VAC-SLY vaccinated pigs had meningitis whereas two of the VAC-SCF and two of the placebo vaccinated pigs did so. All the samples of brain, lung and tarsus taken from the VAC-SLY vaccinated pigs were sterile whereas S suis was reisolated from most of these tissues from the other groups.




This article has been cited by other articles:


Home page
 CVIHome page
Y. Li, M. Gottschalk, M. Esgleas, S. Lacouture, J. D. Dubreuil, P. Willson, and J. Harel
Immunization with Recombinant Sao Protein Confers Protection against Streptococcus suis Infection
Clin. Vaccine Immunol., August 1, 2007; 14(8): 937 - 943.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
Y. Li, G. Martinez, M. Gottschalk, S. Lacouture, P. Willson, J. D. Dubreuil, M. Jacques, and J. Harel
Identification of a Surface Protein of Streptococcus suis and Evaluation of Its Immunogenic and Protective Capacity in Pigs
Infect. Immun., January 1, 2006; 74(1): 305 - 312.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
O. Okwumabua and S. Chinnapapakkagari
Identification of the Gene Encoding a 38-Kilodalton Immunogenic and Protective Antigen of Streptococcus suis
Clin. Vaccine Immunol., April 1, 2005; 12(4): 484 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. J. King, P. J. Heath, I. Luque, C. Tarradas, C. G. Dowson, and A. M. Whatmore
Distribution and Genetic Diversity of Suilysin in Streptococcus suis Isolated from Different Diseases of Pigs and Characterization of the Genetic Basis of Suilysin Absence
Infect. Immun., December 1, 2001; 69(12): 7572 - 7582.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. G. Allen, S. Bolitho, H. Lindsay, S. Khan, C. Bryant, P. Norton, P. Ward, J. Leigh, J. Morgan, H. Riches, et al.
Generation and Characterization of a Defined Mutant of Streptococcus suis Lacking Suilysin
Infect. Immun., April 1, 2001; 69(4): 2732 - 2735.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Allgaier, R. Goethe, H. J. Wisselink, H. E. Smith, and P. Valentin-Weigand
Relatedness of Streptococcus suis Isolates of Various Serotypes and Clinical Backgrounds as Evaluated by Macrorestriction Analysis and Expression of Potential Virulence Traits
J. Clin. Microbiol., February 1, 2001; 39(2): 445 - 453.
[Abstract] [Full Text]

Home page
 Infect. Immun.Home page
N. Charland, V. Nizet, C. E. Rubens, K. S. Kim, S. Lacouture, and M. Gottschalk
Streptococcus suis Serotype 2 Interactions with Human Brain Microvascular Endothelial Cells
Infect. Immun., February 1, 2000; 68(2): 637 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
B. H. Jost, J. G. Songer, and S. J. Billington
An Arcanobacterium (Actinomyces) pyogenes Mutant Deficient in Production of the Pore-Forming Cytolysin Pyolysin Has Reduced Virulence
Infect. Immun., April 1, 1999; 67(4): 1723 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. Chatellier, M. Gottschalk, R. Higgins, R. Brousseau, and J. Harel
Relatedness of Streptococcus suis Serotype 2 Isolates from Different Geographic Origins as Evaluated by Molecular Fingerprinting and Phenotyping
J. Clin. Microbiol., February 1, 1999; 37(2): 362 - 366.
[Abstract] [Full Text]

Home page
 J. Clin. Microbiol.Home page
J. Staats, B. Plattner, J Nietfeld, S Dritz, and M. Chengappa
Use of ribotyping and hemolysin activity to identify highly virulent Streptococcus suis type 2 isolates [In Process Citation]
J. Clin. Microbiol., January 1, 1998; 36(1): 15 - 19.
[Abstract] [Full Text]


HOME CURRENT ISSUE TABLE OF CONTENTS ARCHIVE SEARCH SUBSCRIPTIONS JOBS FEEDBACK HELP
Copyright © 1996 British Veterinary Association